Pipeline - Biomica

Immuno-oncology

Recent evidence underscores the role of the microbiome in cancer therapy response, particularly in its impact on immune checkpoint inhibitors like PD-1/PD-L1. As research unfolds, it becomes increasingly apparent that modulating the intestinal microbiome could serve as a novel and effective adjunct mean to augment current anti-cancer treatments.

Program
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Approach

BMC128

Combination Therapy with ICI for Solid Tumors

Program
Discovery
Preclinical
Phase 1
Phase 2
Phase 3

Approach

Biological

Harnessing our computational analysis and predictive capabilities, we have identified BMC128, a rationally designed microbial consortium.

Developed as a Live Bacterial Product (LBP), BMC128 is an LBP consortium comprised of four unique bacterial strains, natural inhabitants of the human intestinal tract, that harbor specific functional capabilities with the potential to enhance immunological therapeutic responses and facilitate anti-tumor immune activity through multiple biological processes.

GI related disorders

Research increasingly points to a correlation between intestinal microbiome alterations and chronic gastrointestinal (GI) diseases. The expanding comprehension of the microbiota’s role in GI biochemical, immunological, and physiological functions has heightened interest in harnessing it for GI disorder treatment.

Current interventions, including antibiotics, prebiotics, probiotics, and fecal microbiome transplant (FMT), have shown inconsistent beneficial effects, stressing the need for rationally-designed LBP products that specifically target disease physiology. Biomica focuses on two microbiome-driven GI disorders: inflammatory bowel diseases (IBD) and functional GI and motility disorders (e.g., irritable bowel syndrome).

Program
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Approach

BMC333

IBD

Program
Discovery
Preclinical
Phase 1
Phase 2
Phase 3

Approach

Biological

IBD

IBD includes conditions such as ulcerative colitis and Crohn’s disease, which are chronic, debilitating, non-infectious, inflammatory diseases of the digestive tract.

Utilizing our computational predictive biology capabilities, we have identified BMC333: a rationally-designed live microbial consortium with potential anti-inflammatory activity in IBD. BMC333 is designed to restore diversity and specific functionality to a microbial community with individually selected, cultured bacteria. BMC333 is comprised of bacterial strains selected for their multiple desired functions to achieve maximal functional activity with only four bacterial strains. this LBP is aimed to result in robust immune modulation through several underlying and complementary anti-inflammatory modes of action.

BMC426

IBS

Program
Discovery
Preclinical
Phase 1
Phase 2
Phase 3

Approach

Biological

IBS

Irritable bowel syndrome (IBS) is a chronic digestive system disorder estimated to affect 4.1% of the world population [1]. IBS-affected individuals suffer from abdominal pain, bloating, and abnormal bowel movements; that often affect their daily functioning and quality of life. Current standard therapies for IBS are limited, particularly in relation to IBS-associated abdominal pain. Studies have pointed to associations between alterations in the gut microbiome and IBS, suggesting microbiome involvement in developing IBS symptoms[2].

In our IBS program, we leverage proprietary data from several US-based clinical trials to develop a novel microbiome-based drug.

BMC426 and BMC427, are Biomica’s two rationally designed LBP-consortia aimed to restore specific functionality to the patients’ microbial community with individually selected, cultured bacteria. BMC426 and BMC427 are comprised of bacterial strains selected for their multiple desired functions to achieve maximal functional activity with only 4 or 5 bacterial strains, respectively. These LBP’s are aimed to result in robust metabolic and enteric neurotransmitters’ modulation, and affect IBS through several underlying and complementary modes of action.

Antimicrobial Resistance (AMR)

Program
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Approach

BMC202

C difficile Infection

Program
Discovery
Preclinical
Phase 1
Phase 2
Phase 3

Approach

Small-molecule

Antibiotic-Resistant Bacteria: Clostridioides difficile Infection (CDI)— Is a pervasive hospital-acquired infection posing a significant public health threat, with an annual economic toll of $5.4 billion in the US alone.

Utilizing our microbiome therapeutics platform, we’re advancing BMC201—a small-molecule drug candidate designed to combat the primary toxin produced by Clostridioidesdifficile. BMC201 is formulated for oral administration, with our therapeutic strategy aimed at mitigating dysbiosis in the colonic microbiome amid recurrent CDI.

By specifically targeting the toxin secreted by Clostridioides difficile, we develop a highly selective treatment option designed to alleviate CDI-related symptoms. Unlike conventional antibiotic therapies, our approach preserves the patient’s vital commensal intestinal microbial community.

BMC230

MRSA Infection

Program
Discovery
Preclinical
Phase 1
Phase 2
Phase 3

Approach

Small-molecule

MRSA, a multi-drug resistant bacterium, responsible for several difficult-to-treat infections in humans, leading to tens of thousands of annual cases of mortality in the US.
Biomica is engaged in a collaboration with Prof. Ada Yonath’s, Nobel Prize laureate, at the Weizmann Institute of Science in Israel to develop a selective treatment against antibiotic resistant strains of Staphylococcus aureus infection, in a microbiome focused approach.

Biomica pushes the barriers by addressing the root cause of the disorder

Immuno-oncology

BMC128

BMC333

BMC426

Antimicrobial Resistance (AMR)

BMC202

BMC230

Contact Us